Over the opposition of plaintiffs’ counsel, Pfizer’s counsel in the Zoloft multidistrict litigation in which women allege that their use of the antidepressant caused birth defects in their children said they will be moving to transfer into the MDL a class action in which plaintiffs allege that the drug functions little better than a placebo.
The decision will be up to the Judicial Panel on Multidistrict Litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
